Compare Cassava Sciences Inc (FLNA) vs Old Dominion Freight Line Inc (ODFL) Price & Performance

Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).

The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.

ODFL trades at $175.61, down 1.35% on the day, with a bearish technical signal but strong fundamentals including a 19.44% net income margin and consistent earnings beats. The company recently announced a 4.9% general rate increase effective October 5, 2026, to offset rising costs and support service investments. Despite a high P/E ratio of 34.95, robust profitability and positive cash flow trends underpin the stock's valuation.

The outlook is mixed: analyst consensus is a buy with a $230.93 price target, implying significant upside, but near-term technical pressure and valuation concerns present risks. Key catalysts include execution of the rate increase and Q3 2026 earnings, while macroeconomic pressures on freight demand remain a headwind.